Company: EDSA
Filing Date: 2025-03-11
Form Type: 424B3
Source: 0001171843-25-001403
Chunk: 17

Company: Edesa Biotech, Inc.
Filing Date: 2025-03-11
Form: 424B3
Chunk 17
---
 if any, for each series; (iii) the price at
which, and the terms and conditions on which, the preferred shares of each series may be redeemed, if such shares are redeemable; (iv)
the terms and conditions, if any, upon which preferred shares of such series may be converted into shares of other classes or series of
shares of the Company, or other securities; and (v) the maturity date, if any, for each such series; but no such special rights or restriction
shall contravene any other provision of Part 26 of our Articles.

The issuance of preferred shares may
or may not have a dilutive effect on the voting rights of shareholders owning common shares, depending on the rights and preferences set
by the board of directors. Preferred shares may be issued quickly with terms designed to delay or prevent a change in control of our company
or make removal of management more difficult. However, except for such rights relating to the election of directors on a default in payment
of dividends as may be attached to any series of the preferred shares by the board of directors or in connection with convertible preferred
shares, the holders of preferred shares shall not be entitled, as such, to receive notice of, or to attend or vote at, any general meeting
of our shareholders. Section 61 of the British Columbia Business Corporations Actprovides that the special rights attached to
preferred shares may not be prejudiced or interfered with unless the shareholders holding such class of shares consent to such matter
by a special resolution of such holders of preferred shares. Additionally, the issuance of preferred shares may have the effect of decreasing
the market price of our common shares.

| 14 |

#### Series A-1 Convertible Preferred Shares
On October 30, 2024, we filed Amended
and Restated Articles to amend our authorized share structure to amend the terms of a series of preferred shares, without par value, designated
as “Series A-1 Convertible Preferred Shares” (the “Series A-1 Shares”). We are authorized to issue up to 500 Series
A-1 Shares.

The Series A-1 Shares have a stated
value of $10,000 per share and rank, with respect to redemption payments, rights upon liquidation, dissolution or winding-up of the Company,
or otherwise, senior in preference and priority to our common shares, but equal to other series of preferred shares. Until the three-year
anniversary of the day of issuance, holders of the Series